Ascend Capital’s Biogen BIIB Stock Holding History

Ascend Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-43,945	Closed	-$12.8M	–	179
2018 Q2	$12.8M	Buy	43,945 +30,974	+239%	+$8.71M	0.6%	58
2018 Q1	$3.55M	Buy	+12,971	New	+$4.03M	0.14%	135
2017 Q3	–	Sell	-66,053	Closed	-$17.9M	–	168
2017 Q2	$17.9M	Buy	+66,053	New	+$17.5M	0.83%	42
2016 Q3	–	Sell	-5,070	Closed	-$1.23M	–	123
2016 Q2	$1.23M	Sell	5,070 -4,930	-49%	-$1.3M	0.08%	127
2016 Q1	$2.6M	Sell	10,000 -136,225	-93%	-$36M	0.25%	78
2015 Q4	$44.8M	Buy	146,225 +66,345	+83%	+$19.1M	1.58%	16
2015 Q3	$23.3M	Buy	79,880 +10,696	+15%	+$3.53M	0.91%	39
2015 Q2	$27.9M	Buy	+69,184	New	+$27.8M	0.92%	42
2015 Q1	–	Sell	-40,313	Closed	-$13.7M	–	171
2014 Q4	$13.7M	Sell	40,313 -55,083	-58%	-$17.8M	0.53%	65
2014 Q3	$31.6M	Buy	+95,396	New	+$31.5M	0.93%	41
2014 Q2	–	Sell	-10,010	Closed	-$3.06M	–	172
2014 Q1	$3.06M	Sell	10,010 -196,949	-95%	-$62.5M	0.08%	163
2013 Q4	$57.9M	Buy	206,959 +119,519	+137%	+$30.9M	1.76%	10
2013 Q3	$21.1M	Buy	+87,440	New	+$19.6M	0.78%	40

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ascend Capital's BIIB Position: Q3 2018 in Review

Ascend Capital sold out of Biogen (BIIB) in Q3 2018, closing a stake of 43,945 shares — an estimated $12.8M sold.

Ascend Capital first reported a position in BIIB in Q3 2013 and held it in 13 quarters. The position peaked at $57.9M in Q4 2013. 1,146 funds tracked by Wall St. Rank hold BIIB as of Q3 2018.

Ascend Capital reported no remaining Biogen position as of Q3 2018 after selling out during the quarter.
Ascend Capital sold 43,945 Biogen shares in Q3 2018, an estimated $12.8M.
Ascend Capital first reported a position in Biogen in Q3 2013 and held it in 13 quarters.
Ascend Capital's Biogen position peaked at $57.9M in Q4 2013.
1,146 funds tracked by Wall St. Rank held Biogen as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.